%0 Journal Article
%T 特发性膜性肾病免疫抑制治疗的最新研究进展<br>Advanced Progress in Immunosuppressive Therapy for Idiopathic Membranous Nephropathy
%A 杨艳江
%A 杨向东
%J Advances in Clinical Medicine
%P 7085-7094
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.135990
%X 特发性膜性肾病(Idiopathic membranous nephropathy, IMN)是肾病综合征常见的病因，IMN发病率逐年增加，大约1/3的IMN患者自行缓解，1/3的患者进展为终末期肾脏病，针对高风险的IMN需采取治疗，延缓其进入尿毒症期。目前主要药物包括皮质类固醇激素、烷化剂、钙调磷酸酶抑制剂(他克莫司、环孢素A)、霉酚酸酯、促肾上腺皮质激素、利妥昔单抗及新型抗CD20单克隆抗体。<br />
Idiopathic membranous nephropathy (IMN) is one of the most common causes of nephrotic syn-drome, and its incidence rate is increasing year by year, with approximately 1/3 of IMN patients remiss to their own and 1/3 patients progressing to end-stage renal disease, and treatment is needed for high-risk IMN to delay its progression to uremic stage. Current drugs include cortico-steroids, alkylating agents, calcineurin inhibitors (tacrolimus, cyclosporine), mycophenolate mofetil, adrenocorticotropic hormone, rituximab, and anti-CD20 monoclonal antibodies.
%K 特发性膜性肾病，利妥昔单抗，新型抗CD20单克隆抗体<br>Idiopathic Membranous Nephropathy
%K Rituximab
%K Anti-CD20 Monoclonal Antibodies
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=64979